Neoantigen Peptide Vaccine clinical trials
How each study uses Neoantigen Peptide Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Neoantigen Peptide Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Neoantigen Peptide Vaccine
- 4
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Mayo Clinic (1) · Fred Hutchinson Cancer Center (1) · The First Affiliated Hospital of Nanchang University (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Neoantigen Peptide Vaccine.
Studies
Open first, then newest update. How each study uses Neoantigen Peptide Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingPhase 1/2Mayo ClinicNCT05269381Written as Neoantigen Peptide Vaccine
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT05098210Written as Neoantigen Peptide Vaccine
- Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid TumorsRecruitingNot applicableThe First Affiliated Hospital of Nanchang UniversityNCT05749627Written as Neoantigen peptide vaccine
- Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyTerminatedPhase 1Washington University School of MedicineNCT03956056Written as Neoantigen Peptide Vaccine